{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:53:09Z","timestamp":1780779189235,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The present study sought to differentiate multiple sclerosis and neuromyelitis optica spectrum disorder patients at their first attack by describing and distinguishing their clinical features, radiographic characteristics, and immunologic characteristics of serum and cerebrospinal fluid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively studied 58 patients with multiple sclerosis (MS) and 52 patients with neuromyelitis optica spectrum disorder (NMOSD) by referencing brainstem lesions as the prodromal events. Their demographics and presentation at the time of the first attack was evaluated including their gender, age, clinical features of the first attack, the expanded disability status scale (EDSS), brainstem lesion(s) by head MRI, and immunological indices of serum and cerebrospinal fluid.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The NMOSD group had more female patients (4.8 vs. 1.9, <jats:italic>p<\/jats:italic> &amp;lt; 0.05), and was older than the MS group (37.81 \u00b1 16.60 vs. 27.57 \u00b1 11.17, <jats:italic>p<\/jats:italic> &amp;lt;0.001). NMOSD patients also had a significantly higher association with autoimmune diseases or positive autoimmune antibodies (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). There was no significant difference in the EDSS scores between the two groups (<jats:italic>p<\/jats:italic> = 0.420). Central hiccups, vomiting, and pyramidal tract signs were more common in the NMOSD group than the MS group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> &amp;lt; 0.01), while eye movement abnormalities were more common with MS (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). There were no significant differences in other clinical manifestations such as vertigo, diplopia, limb weakness, numbness, and eating difficulty. MS patients were more likely to have midbrain and pons imaging lesions (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), while NMOSD patients had more lesions in the medulla oblongata (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). The lesions in the MS group were mostly located in the periphery, while those in the NMOSD group were centrally located (<jats:italic>p<\/jats:italic> &amp;lt; 0.001, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Patchy lesions were more common in MS patients (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), while large lesions were more common in the NMOSD group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Finally, serum AQP4 Ab was found only in the NMOSD group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with MS and NMOSD have differentiating clinical manifestations at the time of their first brainstem lesions which include central hiccups, vomiting, pyramidal tract signs, and abnormal eye movements. Additionally, distinct imaging manifestations such as lesion location(s) and morphology may also aid in the development of pathognomonic criteria leading to timely initial diagnosis of MS and NMOSD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.836337","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T05:08:46Z","timestamp":1652072926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heralding Prodrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiling","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the mcdonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J Investig Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","author":"Doshi","year":"2016","journal-title":"Clin Med (Lond)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fneur.2020.00450","article-title":"Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"11","author":"Kuchling","year":"2020","journal-title":"Front Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics."},{"key":"B10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of nmo spectrum disorder and mog-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/ern.13.18","article-title":"Evaluation of brainstem involvement in multiple sclerosis","volume":"13","author":"Habek","year":"2013","journal-title":"Expert Rev Neurother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated cns conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3174\/ajnr.A5663","article-title":"Imaging differences between neuromyelitis optica spectrum disorders and multiple sclerosis: a multi-institutional study in Japan","volume":"39","author":"Tatekawa","year":"2018","journal-title":"AJNR Am J Neuroradiol."},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume-title":"Cold Spring Harb Perspect Med","author":"Klineova","year":"2018"},{"key":"B16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1212\/NXI.0000000000000583","article-title":"Collaborative international research in clinical and longitudinal experience study in nmosd","volume":"6","author":"Cook","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of ms in the united states: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"20552173211006862","DOI":"10.1177\/20552173211006862","article-title":"Aqp4-igg autoimmunity in japan and germany: differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders","volume":"7","author":"Asseyer","year":"2021","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (nemos)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation."},{"key":"B24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4137\/CCRep.S15177","article-title":"Systemic lupus erythematosus (sle) complicated by neuromyelitis optica (nmo - devic's disease): clinic-pathological report and review of the literature","volume":"7","author":"Adawi","year":"2014","journal-title":"Clin Med Insights Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0137715","DOI":"10.1371\/journal.pone.0137715","article-title":"Imaging surrogates of disease activity in neuromyelitis optica allow distinction from multiple sclerosis","volume":"10","author":"Matthews","year":"2015","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7100138","article-title":"Pattern recognition of the multiple sclerosis syndrome","volume-title":"Brain Sci","author":"Zabad","year":"2017"},{"key":"B29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/WNO.0000000000000507","article-title":"Ocular motor manifestations of multiple sclerosis","volume":"37","author":"Nerrant","year":"2017","journal-title":"J Neuroophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1177\/1352458508096878","article-title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","volume":"14","author":"Miller","year":"2008","journal-title":"Mult Scler."},{"key":"B31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler."},{"key":"B32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12883-016-0721-1","article-title":"The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica","volume":"16","author":"Cheng","year":"2016","journal-title":"BMC Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.msard.2017.03.011","article-title":"Neuromyelitis optica presenting with horner syndrome: a case report and review of literature","volume":"14","author":"Uludag I","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish ms from aqp4-antibody nmosd and mog-antibody disease","volume":"88","author":"Jury\u0144czyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"Nakamura","year":"2009","journal-title":"Mult Scler."},{"key":"B37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study","volume":"255","author":"Nakamura","year":"2008","journal-title":"J Neurol."},{"key":"B38","article-title":"Distinctive lesions of brain mri between mog-antibody-associated and aqp4-antibody-associated diseases","volume-title":"J Neurol Neurosurg Psychiatry","author":"Matsumoto","year":"2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bpa.12386","article-title":"Early and extensive spinal white matter involvement in neuromyelitis optica","volume":"27","author":"Hayashida","year":"2017","journal-title":"Brain Pathol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.836337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T05:08:50Z","timestamp":1652072930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.836337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":39,"alternative-id":["10.3389\/fneur.2022.836337"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.836337","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"836337"}}